MYO - Myomo Inc Stock Price, Fair Value and News

3.39USD-0.03 (-0.88%)Market Closed

Market Summary

USD3.39-0.03

Market Closed

-0.88%

MYO Alerts

1 major insider buys recently.

MYO Stock Price

View Fullscreen

MYO RSI Chart

MYO Valuation

Market Cap

96.6M

Price/Earnings (Trailing)

-11.85

Price/Sales (Trailing)

5.02

EV/EBITDA

-11.46

Price/Free Cashflow

-15.28

MYO Price/Sales (Trailing)

MYO Profitability

Operating Margin

68.51%

EBT Margin

-41.53%

Return on Equity

-90.64%

Return on Assets

-55.88%

Free Cashflow Yield

-6.54%

MYO Fundamentals

MYO Revenue

Revenue (TTM)

19.2M

Rev. Growth (Yr)

17.69%

Rev. Growth (Qtr)

-6.36%

MYO Earnings

Earnings (TTM)

-8.1M

Earnings Growth (Yr)

-13.5%

Earnings Growth (Qtr)

-21.25%

Breaking Down MYO Revenue

Last 7 days

6.3%

Last 30 days

-3.1%

Last 90 days

4.0%

Trailing 12 Months

474.4%

How does MYO drawdown profile look like?

MYO Financial Health

Current Ratio

2.49

MYO Investor Care

Shares Dilution (1Y)

36.16%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	15.1M	17.4M	18.5M	19.2M
2022	15.4M	16.0M	15.5M	15.6M
2021	8.9M	11.2M	13.6M	13.9M
2020	4.0M	4.0M	5.3M	7.6M
2019	3.0M	3.2M	3.2M	3.8M
2018	1.7M	2.0M	2.1M	2.4M
2017	1.2M	1.3M	1.4M	1.6M
2016	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Myomo Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	kovelman harry	sold (taxes)	-433	2.97	-146	chief medical officer
Mar 14, 2024	kirk thomas f	bought	175,000	3.5	50,000	-
Mar 11, 2024	mitchell micah	sold (taxes)	-18,810	3.51	-5,359	chief commercial officer
Mar 11, 2024	henry david a	sold (taxes)	-27,286	3.51	-7,774	chief financial officer
Mar 11, 2024	kovelman harry	sold (taxes)	-23,130	3.51	-6,590	chief medical officer
Mar 05, 2024	kovelman harry	sold (taxes)	-570	3.88	-147	chief medical officer
Feb 05, 2024	kovelman harry	sold (taxes)	-468	3.21	-146	chief medical officer
Jan 19, 2024	morris milton mayo	acquired	95,000	3.8	25,000	-
Jan 03, 2024	kovelman harry	sold (taxes)	-680	4.69	-145	chief medical officer
Dec 08, 2023	crowley thomas aloysius jr.	sold	-	-	-14,997	-

Which funds bought or sold MYO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Rosalind Advisors, Inc.	added	27.49	-1,614,640	8,004,110	7.48%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	5,000	5,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-56,583	-	-%
Apr 23, 2024	Accurate Wealth Management, LLC	unchanged	-	-22,643	68,791	0.02%
Apr 19, 2024	Accel Wealth Management	new	-	135,319	135,319	0.06%
Apr 16, 2024	Stratos Wealth Partners, LTD.	added	100	38,250	163,500	-%
Apr 15, 2024	Legato Capital Management LLC	new	-	711,307	711,307	0.09%
Mar 11, 2024	VANGUARD GROUP INC	added	664	5,923,620	6,100,310	-%
Feb 26, 2024	Virtu Financial LLC	new	-	112,000	112,000	0.01%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	243,867	243,867	-%

Are Funds Buying or Selling MYO?

Are funds buying MYO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MYO

No. of Funds

MYO Alerts

1 major insider buys recently.

Unveiling Myomo Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	9.9%	2,447,740	SC 13G/A
Feb 14, 2024	rosalind advisors, inc.	9.2%	2,433,740	SC 13G/A
Feb 14, 2024	rosalind advisors, inc.	9.2%	2,433,740	SC 13G/A
Feb 14, 2024	packer paul	0.0%	0	SC 13G/A
Feb 07, 2024	hirschman orin	9.9%	2,838,290	SC 13G/A
Sep 07, 2023	hirschman orin	9.6%	2,540,000	SC 13G/A
Aug 31, 2023	triple gate partners, lp	9.36%	2,482,782	SC 13G/A
Aug 28, 2023	rosalind advisors, inc.	9.8%	2,611,418	SC 13G/A
Mar 28, 2023	strategic risk, llc.	5.1%	1,057,279	SC 13G
Feb 15, 2023	hewlett fund lp	780%	1e+06	SC 13G/A

Recent SEC filings of Myomo Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	SC 13G/A	Major Ownership Report
Apr 04, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent
Mar 28, 2024	3	Insider Trading
Mar 28, 2024	8-K	Current Report
Mar 18, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading

Peers (Alternatives to Myomo Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

Myomo Inc News

Latest updates

Myomo Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-6.4%	4,756,383	5,079,523	5,958,544	3,446,708	4,041,527	3,968,201	3,677,575	3,867,926	4,031,634	4,383,957	3,104,294	2,336,489	3,789,976	1,926,660	858,590	1,008,145	1,520,696	606,619	880,349	830,066	889,575
Cost Of Revenue	3.8%	1,651,522	1,590,675	1,677,488	1,139,074	1,408,842	1,331,217	1,276,444	1,290,704	909,175	1,110,204	901,566	623,152	1,007,524	855,338	418,862	318,651	424,646	329,227	380,093	286,802	226,176
Gross Profit	-11.0%	3,104,862	3,488,848	4,281,056	2,307,634	2,632,685	2,636,984	2,401,131	2,577,222	3,122,459	3,273,753	2,202,728	1,713,337	2,782,452	1,071,322	439,728	689,494	1,096,051	277,392	500,256	543,264	663,399
Operating Expenses	0.5%	5,538,055	5,513,217	5,384,062	4,978,599	4,856,862	5,455,625	5,296,960	5,315,953	5,828,190	5,304,024	4,802,360	4,645,769	4,469,063	3,616,423	3,288,275	4,111,921	3,676,867	3,102,440	3,206,600	3,226,059	3,398,426
S&GA Expenses	-2.8%	4,660,049	4,795,961	4,819,827	4,501,608	4,357,188	4,765,218	4,664,088	4,656,417	5,039,348	4,662,796	4,202,244	4,119,802	4,050,305	3,270,757	2,890,464	3,604,968	3,234,344	2,669,375	2,779,027	2,779,711	2,868,807
R&D Expenses	22.4%	878,006	717,256	564,235	476,991	499,674	690,407	632,872	659,536	788,842	641,228	600,116	525,967	418,758	345,666	397,811	506,953	442,523	433,065	427,573	446,348	529,619
EBITDA Margin	0.9%	-0.41	-0.41	-0.47	-0.67	-0.66	-0.69	-0.63	-0.63	-0.72	-0.66	-0.87	-1.16	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,135	40,025	166,643	-	-	-	-	-
Income Taxes	52.7%	70,798	46,355	-3,562	42,411	-23,265	23,382	-6,435	76,255	22,324	22,696	15,665	28,243	-	1,153	1,085	613	-	-	-	-	-
Earnings Before Taxes	-20.5%	-2,389,307	-1,982,660	-1,017,712	-2,601,884	-2,190,715	-2,806,334	-2,915,357	-2,738,679	-2,710,874	-2,034,326	-2,605,650	-2,932,551	-1,701,264	-2,775,418	-3,285,849	-3,801,380	-	-2,788,118	-2,565,327	-2,598,060	-
EBT Margin	1.3%	-0.42	-0.42	-0.49	-0.69	-0.68	-0.72	-0.65	-0.66	-0.74	-0.68	-0.90	-1.20	-	-	-	-	-	-	-	-	-
Net Income	-21.2%	-2,460,104	-2,029,016	-1,014,150	-2,644,295	-2,167,450	-2,829,716	-2,908,922	-2,814,934	-2,733,198	-2,057,022	-2,621,315	-2,960,794	-1,698,413	-2,776,571	-3,286,934	-3,801,993	-2,761,504	-2,788,118	-2,565,327	-2,598,060	-2,691,954
Net Income Margin	0.1%	-0.42	-0.42	-0.50	-0.70	-0.69	-0.73	-0.66	-0.66	-0.75	-0.69	-0.90	-1.20	-	-	-	-	-	-	-	-	-
Free Cashflow	-35.0%	-2,387,410	-1,768,899	-300,496	-1,861,775	-2,467,606	-2,804,460	-2,700,790	-2,372,479	-1,871,630	-2,254,883	-3,603,155	-2,144,489	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-14.5%	14,582	17,054	13,297	13,736	10,162	12,157	14,562	17,977	20,095	17,459	17,709	20,923	14,710	15,357	12,828	15,912	6,599	6,083	8,543	11,100	8,282
Current Assets	-14.9%	13,651	16,042	12,630	12,912	9,215	11,052	13,305	16,605	19,092	16,461	16,632	19,929	14,446	15,176	12,643	15,566	6,149	5,703	8,167	10,719	7,874
Cash Equivalents	-0.6%	6,871	6,912	6,006	9,264	5,346	7,400	10,236	12,943	15,524	12,607	13,772	17,371	12,241	13,318	10,733	13,726	4,465	4,328	6,669	9,234	6,541
Inventory	21.5%	1,804	1,485	1,337	1,565	1,400	1,483	1,261	1,029	808	644	729	794	707	760	679	603	440	454	349	301	256
Net PPE	2.2%	176	172	154	191	194	240	283	280	275	302	320	210	95.00	106	110	139	155	170	193	173	188
Liabilities	-7.3%	5,592	6,031	4,477	4,104	3,803	4,335	4,214	5,107	4,686	4,312	3,897	4,856	3,144	2,374	2,775	4,129	4,774	1,664	1,436	1,578	1,856
Current Liabilities	-5.2%	5,477	5,778	4,337	3,934	3,602	4,114	3,884	4,653	4,283	3,723	3,220	4,097	2,870	2,207	2,688	4,128	3,884	1,663	1,436	1,578	1,856
Shareholder's Equity	-18.4%	8,989	11,023	8,820	9,632	6,359	7,822	10,348	12,870	15,409	13,148	13,811	16,067	11,565	12,983	10,053	11,783	6,426	4,419	7,061	9,436	6,426
Retained Earnings	-2.6%	-96,930	-94,470	-92,441	-91,427	-88,783	-86,615	-83,800	-80,877	-78,062	-75,329	-73,272	-70,650	-67,690	-65,991	-63,214	-59,927	-56,125	-53,364	-50,576	-48,011	-45,412
Additional Paid-In Capital	0.3%	105,840	105,506	101,227	100,955	95,105	94,455	94,149	93,804	93,538	88,493	87,091	86,728	79,274	78,980	73,274	71,717	57,957	57,789	57,688	57,537	51,722
Shares Outstanding	2.3%	27,135	26,515	21,092	20,923	7,751	7,064	6,924	6,886	6,870	5,530	5,417	5,191	-	-	-	-	-	-	-	-	-
Float	-	-	-	9,527	-	-	-	10,011	-	-	-	60,192	-	-	-	11,896	-	-	-	11,077	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-37.4%	-2,355	-1,714	-285	-1,816	-2,464	-2,798	-2,648	-2,322	-1,828	-2,209	-3,396	-2,112	-1,132	-1,789	-3,665	-2,445	-2,644	-2,290	-2,287	-3,119	-2,513
Share Based Compensation	1.1%	334	330	280	171	273	306	345	266	265	302	363	166	203	182	106	123	168	147	386	208	172
Cashflow From Investing	274.4%	2,294	-1,315	-2,963	-45.08	-3.38	-5.74	-52.79	-248	-23.93	-54.88	-203	-44.49	-15.46	-22.42	-	-7.88	-13.73	-3.36	-29.50	-5.40	-9.50
Cashflow From Financing	-100.0%	31*	3,950	-8.15	5,772	377	-	-	-	4,780	1,099	1.00	7,288	19.00	4,375	673	11,714	2,795	-46.88	-247	5,818	-30.11

MYO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 19,241,158	$ 15,555,229
Cost of revenue	6,058,775	5,302,133
Gross profit	13,182,383	10,253,096
Operating expenses:
Research and development	2,636,487	2,482,489
Selling, general and administrative	18,777,445	18,442,811
Total operating expenses	21,413,932	20,925,300
Loss from operations	(8,231,549)	(10,672,204)
Other expense (income)
Interest income	(410,274)	(88,731)
Other expense, net	785	1,101
Loss on equity investment	169,503	66,511
Total other expense (income)	(239,986)	(21,119)
Loss before income taxes	(7,991,563)	(10,651,085)
Income tax expense	156,002	69,937
Net loss	$ (8,147,565)	$ (10,721,022)
Weighted average number of common shares outstanding:
Basic and diluted	29,499,341	7,051,447
Basic and diluted	29,499,341	7,051,447
Net loss per share available to common stockholders:
Basic and diluted	$ (0.28)	$ (1.52)
Basic and diluted	$ (0.28)	$ (1.52)
Product [Member]
Revenue	$ 17,476,238	$ 14,555,229
License [Member]
Revenue	$ 1,764,920	$ 1,000,000

MYO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 6,871,306	$ 5,345,967
Short-term investments	1,994,662	0
Accounts receivable, net	2,382,658	1,896,163
Inventories, net	1,803,507	1,399,865
Prepaid expenses and other current assets	598,850	573,462
Total Current Assets	13,650,983	9,215,457
Equipment, net	175,794	194,283
Operating lease assets with right-of-use	663,554	508,743
Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd.	0	132,489
Other Assets	91,237	111,034
Total Assets	14,581,568	10,162,006
Current Liabilities:
Accounts payable and accrued expenses	4,885,944	3,179,362
Current operating lease liabilities	486,143	353,701
Income taxes payable	96,461	48,220
Deferred revenue	8,510	20,653
Total Current Liabilities	5,477,058	3,601,936
Non-current operating lease liability	115,160	200,207
Deferred revenue	0	498
Total Liabilities	5,592,218	3,802,641
Commitments and Contingencies - Note 10	0	0
Stockholders’ Equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock par value $0.0001 per share 65,000,000 shares authorized; 27,135,061 and 7,750,635 shares issued as of December 31, 2023 and 2022, respectively, and 27,135,034 and 7,750,608 shares outstanding as of December 31, 2023 and 2022, respectively.	2,715	775
Additional paid-in capital	105,840,239	95,105,071
Accumulated other comprehensive income	83,669	43,227
Accumulated deficit	(96,930,809)	(88,783,244)
Treasury stock, at cost; 27 shares of common stock	(6,464)	(6,464)
Total Stockholders’ Equity	8,989,350	6,359,365
Total Liabilities and Stockholders’ Equity	$ 14,581,568	$ 10,162,006

About Myomo Inc

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, China, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, rehabilitation hospitals and surgery centers, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

CEO	Mr. Paul R. Gudonis
WEBSITE	https://myomo.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	100

Myomo Inc Frequently Asked Questions

What is the ticker symbol for Myomo Inc? What does MYO stand for in stocks?

MYO is the stock ticker symbol of Myomo Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Myomo Inc (MYO)?

As of Fri Apr 26 2024, market cap of Myomo Inc is 96.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MYO stock?

You can check MYO's fair value in chart for subscribers.

What is the fair value of MYO stock?

You can check MYO's fair value in chart for subscribers. The fair value of Myomo Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Myomo Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MYO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Myomo Inc a good stock to buy?

The fair value guage provides a quick view whether MYO is over valued or under valued. Whether Myomo Inc is cheap or expensive depends on the assumptions which impact Myomo Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYO.

What is Myomo Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, MYO's PE ratio (Price to Earnings) is -11.85 and Price to Sales (PS) ratio is 5.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYO PE ratio will change depending on the future growth rate expectations of investors.